MetaVia, Inc. (MTVA)
1.01
-0.06
(-5.61%)
USD |
NASDAQ |
Nov 20, 16:00
1.00
-0.01
(-0.99%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 6.810M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -86.15% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | 2.825 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.0664 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 100.00% |
Profile
| MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing novel pharmaceuticals to treat cardiometabolic diseases. It is developing DA-1726 for the treatment of various cardiometabolic conditions, with potential in both Metabolic and Alcohol-Associated Liver Disease (MetALD) and Alcohol-Associated Liver Disease (ALD), and is advancing vanoglipel (DA-1241) in combination with resmetirom for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company was founded on October 30, 2014 and is headquartered in Cambridge, MA. |
| URL | http://metaviatx.com |
| Investor Relations URL | https://www.metaviatx.com/investor-overview |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Value |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing novel pharmaceuticals to treat cardiometabolic diseases. It is developing DA-1726 for the treatment of various cardiometabolic conditions, with potential in both Metabolic and Alcohol-Associated Liver Disease (MetALD) and Alcohol-Associated Liver Disease (ALD), and is advancing vanoglipel (DA-1241) in combination with resmetirom for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company was founded on October 30, 2014 and is headquartered in Cambridge, MA. |
| URL | http://metaviatx.com |
| Investor Relations URL | https://www.metaviatx.com/investor-overview |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Value |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |